Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization

Bone Marrow Transplantation volume 47, pages 1046–1050 (2012)Cite this article

Subjects

Abstract

The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (>2.0 × 106 CD34+ cells/kg: 81.6%; >5.0 × 106 CD34+ cells/kg: 32.0%) than in NHL patients (>2.0 × 106 CD34+ cells/kg: 64.8%; >5.0 × 106 CD34+ cells/kg: 12.6%; P<0.0001) and also significantly higher in HL patients (>2.0 × 106 CD34+ cells/kg: 81.5%; >5.0 × 106 CD34+ cells/kg: 22.2%) than in NHL patients (P=0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045–1056.

    Article  CAS  PubMed  Google Scholar 

  2. Sola C, Maroto P, Salazar R, Mesia R, Mendoza L, Brunet J et al. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): the CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999; 4: 195–209.

    Article  CAS  PubMed  Google Scholar 

  3. Limat S, Woronoff-Lemsi MC, Milpied N, Chartrin I, Ifrah N, Deconinck E et al. Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. Eur J Cancer 2000; 36: 2360–2367.

    Article  CAS  PubMed  Google Scholar 

  4. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC . The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997; 185: 111–120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hubel K, Liles WC, Broxmeyer HE, Rodger E, Wood B, Cooper S et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004; 1: 165–172.

    Article  PubMed  Google Scholar 

  6. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.

    Article  CAS  PubMed  Google Scholar 

  7. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.

    CAS  PubMed  Google Scholar 

  8. Mohty M, Duarte RF, Croockewit S, Hubel K, Kvalheim G, Russell N . The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 2011; 25: 1–6.

    Article  CAS  PubMed  Google Scholar 

  9. Duarte RF, Shaw BE, Marin P, Kottaridis P, Ortiz M, Morante C et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52–58.

    Article  CAS  PubMed  Google Scholar 

  10. Hubel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011; 46: 1045–1052.

    Article  CAS  PubMed  Google Scholar 

  11. Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2011; 51: 968–975.

    Article  CAS  PubMed  Google Scholar 

  12. Basak GW, Knopinska-Posluszny W, Matuszak M, Kisiel E, Hawrylecka D, Szmigielska-Kaplon A et al. Hematopietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Ann Hematol 2011; 90: 557–568.

    Article  CAS  PubMed  Google Scholar 

  13. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728–2730.

    Article  CAS  PubMed  Google Scholar 

  14. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.

    Article  CAS  PubMed  Google Scholar 

  15. Mendrone Jr A, Arrais CA, Saboya R, Chamone Dde A, Dulley FL . Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci 2008; 39: 187–192.

    Article  PubMed  Google Scholar 

  16. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719–724.

    Article  CAS  PubMed  Google Scholar 

  17. Kuittinen T, Nousiainen T, Halonen P, Mahlamaki E, Jantunen E . Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907–912.

    Article  CAS  PubMed  Google Scholar 

  18. Akhtar S, Weshi AE, Rahal M, Khafaga Y, Tbakhi A, Humaidan H et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin's lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008; 49: 769–778.

    Article  CAS  PubMed  Google Scholar 

  19. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490–499.

    Article  CAS  PubMed  Google Scholar 

  20. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331–338.

    Article  CAS  PubMed  Google Scholar 

  21. Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1253–1261.

    Article  CAS  PubMed  Google Scholar 

  22. D’Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356–363.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Carine Keppens, Genzyme Inc. and Axel Krebs–Brown, Synequanon Inc., for data acquisition and taking part in discussions.

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, University Hospital of Cologne, Cologne, Germany

    K Hübel & M M Fresen

  2. Department of Haematology, Imperial College London, London, UK

    J F Apperley & I H Gabriel

  3. Department of Haematology, Oncology & Internal Diseases, Medical University of Warsaw, Warsaw, Poland

    G W Basak

  4. HPC Transplant Programme, Beatson West of Scotland Cancer Centre, Glasgow, UK

    K W Douglas

  5. Hospitais da Universidade, Coimbra, Portugal

    C Geraldes

  6. Dubrava University Hospital, Zagreb, Croatia

    O Jaksic

  7. Department of Internal Medicine—Hematooncology, Masaryk University Hospital, Brno, Czech Republic

    Z Koristek

  8. University Hospital of Hamburg-Eppendorf, Hamburg, Germany

    N Kröger

  9. Cremona Hospital, Section of Hematology, Cremona, Italy

    F Lanza

  10. Department of Hematology and Oncological Sciences ‘L&A Seràgnoli’, Institute of Hematology, University of Bologna, Bologna, Italy

    R M Lemoli

  11. Department of Haematology & SCT, St Laszlo Hospital, Budapest, Hungary

    G Mikala

  12. Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium

    D Selleslag

  13. Medical University of Vienna, Vienna, Austria

    N Worel

  14. Centre Hospitalier et Universitaire de Nantes, Hématologie Clinique, Nantes, France

    M Mohty

  15. Catalan Institute of Oncology, Idibell, Hospital Duran i Reynals, L’Hospitalet de Llobregat, Barcelona, Spain

    R F Duarte

Authors
  1. K Hübel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M M Fresen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J F Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G W Basak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K W Douglas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I H Gabriel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Geraldes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. O Jaksic
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Z Koristek
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F Lanza
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R M Lemoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G Mikala
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D Selleslag
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. N Worel
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. R F Duarte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Hübel.

Ethics declarations

Competing interests

The authors have also acted as consultants to Genzyme, but the opinions or views expressed in this paper are those of the authors and do not necessarily reflect the opinions or recommendations of Genzyme Corporation.

Additional information

Disclaimer

The material is original research, has not been previously published and has not been submitted for publication elsewhere while under consideration.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hübel, K., Fresen, M., Apperley, J. et al. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant 47, 1046–1050 (2012). https://doi.org/10.1038/bmt.2011.216

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.216

Keywords

This article is cited by

Search

Advanced search

Quick links